[HTML][HTML] Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to …
X Zhuang, Y Jiang, X Yang, L Fu, L Luo… - Frontiers in …, 2023 - frontiersin.org
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic.
X Zhuang, Y Jiang, X Yang, L Fu, L Luo… - Frontiers in …, 2023 - europepmc.org
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to clinic
X Zhuang, Y Jiang, X Yang, L Fu… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
[HTML][HTML] Advances of mesenchymal stem cells and their derived extracellular vesicles as a promising therapy for acute respiratory distress syndrome: from bench to …
X Zhuang, Y Jiang, X Yang, L Fu, L Luo… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …
characterized by diffuse alveolar damage. The period prevalence of ARDS was 10.4% of …